



CIN No. L24232PB1983PLC005426

GST No. 03AAACK6458M1ZB

D.L. No. 1800-OSP, 1804-B

I.E. Code No. 1293001210

KWALITY PHARMACEUTICALS LIMITED

Regd. Office: Village Nag Kalan, Majitha Road, Amritsar - 143 601 (INDIA)

Phone : 91-8558820862 (Accounts)
: 91-8558820863 (Admin.)
: 91-9915743720 (Exports)
M.D. Mobile : 91-9814071215, 9814052314
E-mail : export@kwalitypharma.com
ramesh@kwalitypharma.com
Website : www.kwalitypharma.com

Date: August 11, 2025

To,
The Department of Corporate Services,
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai - 400001

Subject: Submission of standalone and consolidated un-audited financial results for the quarter ended on 30.06.2025 under Regulation 33 of the SEBI (LODR) Regulations, 2015

Ref: Scrip Code: 539997

With respect to captioned subject, we wish to inform you that the Board of Directors in its Meeting held today has inter-alia, considered and approved the standalone and consolidated Un-Audited Financial Results for the quarter ended June 30, 2025.

We are submitting herewith the standalone and consolidated un-audited financial results under Regulation 33 of the Securities and Exchange board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, for the quarter ended as on 30.06.2025 along with the Auditors limited review reports thereon.

The Board Meeting of the Company commenced at 11:30 a.m. and concluded at 01:50 P.M.

Kindly take the above on your record.

Yours Faithfully,

For KWALITY PHARMACEUTICALS LIMITED

ADITYA ARORA

Whole Time Director & CEO

DIN: 07320410



MANAGEMENT DISCUSSION AND ANALYSIS:

Kwality Pharmaceutical Ltd ("KPL") reported a strong start to FY26, with **consolidated revenue rising 39.8% year-on-year**, from ₹80 crore to ₹111.8 crore in Q1. This growth was driven primarily by increased sales of registered products across key international markets.

EBITDA grew 39% YoY, from ₹17.6 crore to ₹24.6 crore. **EBITDA margins remained stable at around 22%**, indicating operational efficiency despite scale-up. **Net profit rose sharply by 43%**, from ₹8.3 crore to ₹11.9 crore, aided by improved scale up.

During the quarter, we successfully completed a regulatory audit of **Zimbabwe**, reinforcing our positioning in the **SAZIBONA and broader African region**. We also showcased our global reach by participating in the **Pharma Expo in Kenya**, with plans to exhibit at several upcoming international marketing expos. These efforts aim to deepen our presence, drive sales, and monetize existing, new and upcoming approvals for our products.

We received **multiple new product registrations** this quarter. This supports our trajectory toward achieving our **₹500 crore revenue target for FY26**.

Importantly, the **EU-GMP audit** for our **general and beta-lactam manufacturing facilities is scheduled for October**, marking a key regulatory milestone in our European expansion efforts from our Amritsar Plant.

On the **biologics front**, Preparations are underway for the **WHO-GMP inspection** of our biologics facility later this year. In parallel, we have initiated **line expansion** to scale up production capacity as we progress towards clinical trials and subsequent commercialization of our **first biological, Erythropoietin (EPO)**.

Kwality continues to focus on building a robust international regulatory footprint, driving margin-accretive growth, and investing in differentiated, high-barrier products for sustained value creation.

Kwality Pharma is a research-driven leader in the export of formulations, specializing in complex and niche injectables. The company operates five state-of-the-art manufacturing facilities that hold necessary regulatory approvals from various regions, including PICs (ANVISA and SFDA), INVIMA, DIGEMED and EUGMP. With a diverse product portfolio exceeding 3,000 formulations across more than 25 therapeutic areas, Kwality Pharma exports its products to over 70 countries worldwide.





CA Amit Handa
F.C.A DISA (ICAI), LL.B, LL.M
(Partner)
9878887600

VIJAY MEHRA & CO.

CHARTERED ACCOUNTANTS

Head Office : D-351, Ranjit Avenue, Amritsar.

CA Ashish Raja
F.C.A. Dip. IFRS B.Com
(Partner)
9899032170

CA Radhika Goel
F.C.A , B.com (Hons.)
(Partner)
9915460831

Ref: _____

Date : 11/8/25

**INDEPENDENT AUDITOR'S REVIEW REPORT ON QUARTERLY UNAUDITED
STANDALONE FINANCIAL RESULTS OF THE COMPANY FOR QUARTER ENDED 30TH
JUNE , 2025 PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS
AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 (AS AMENDED)**

To,

**The Board of Directors of
Kwality Pharmaceuticals Limited.**

1. We have reviewed the accompanying statement of standalone unaudited financial results of **Kwality Pharmaceuticals Limited ("the company) for the quarter ended on 30th June , 2025**, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34) prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

BRANCH OFFICES :

C-2, UGF, FRONT SIDE, RAJAPURI ROAD, NEAR SHANTI NURSING HOME, UTTAM NAGAR, NEW DELHI - 110059
10-E, MALVIYA COMPLEX, LANE NEXT TO NO EXIT, MOHAN MALVIYA ROAD, AMRITSAR - 143001

Email : vijaymehrac@gmail.com, caamithanda@gmail.com, caashishraja09@gmail.com, caradhikagoel@gmail.com





CA Amit Handa
F.C.A DISA (ICAI), LL.B, LL.M
(Partner)
9878887600

VIJAY MEHRA & CO.

CHARTERED ACCOUNTANTS

Head Office : D-351, Ranjit Avenue, Amritsar.



CA Ashish Raja
F.C.A. Dip. IFRS B.Com
(Partner)
9899032170

CA Radhika Goel
F.C.A , B.com (Hons.)
(Partner)
9915460831

Ref: _____

Date : 11/8/25

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with applicable Indian Accounting Standards ("Ind AS") and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

For VIJAY MEHRA & CO.

Chartered Accountants

CA AMIT HANDA

Partner

M. No: 502400

FRN: 001051N

UDIN:- 25502400BMLEHZ3712



Place: Amritsar

Date: 11-08-2025

BRANCH OFFICES :

C-2, UGF, FRONT SIDE, RAJAPURI ROAD, NEAR SHANTI NURSING HOME, UTTAM NAGAR, NEW DELHI - 110059
10-E, MALVIYA COMPLEX, LANE NEXT TO NO EXIT, MOHAN MALVIYA ROAD, AMRITSAR - 143001

Email : vijaymehraca@gmail.com, caamithanda@gmail.com, caashishraja09@gmail.com, caradhikagoel@gmail.com



CA Amit Handa
F.C.A DISA (ICAI), LL.B, LL.M
(Partner)
9878887600

VIJAY MEHRA & CO.

CHARTERED ACCOUNTANTS

Head Office : D-351, Ranjit Avenue, Amritsar.

CA Ashish Raja
F.C.A. Dip. IFRS B.Com
(Partner)
9899032170

CA Radhika Goel
F.C.A, B.com (Hons.)
(Partner)
9915460831

Ref: _____

Date : 11/8/25

INDEPENDENT AUDITOR'S REVIEW REPORT ON THE QUARTERLY UNAUDITED CONSOLIDATED FINANCIAL RESULTS OF THE COMPANY FOR THE QUARTER ENDED 30TH JUNE, 2025 PURSUANT TO THE REGULATION 33 OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015 (AS AMENDED)

To,

**The Board of Directors of
Kwality Pharmaceuticals Limited.**

1. We have reviewed the accompanying statement of Consolidated Unaudited Financial Results of **Kwality Pharmaceuticals Limited** ("the Parent") and its subsidiary (the Parent and its subsidiary together referred to as "the Group"), and its share of the net profit/(loss) after tax and total comprehensive income / loss for the quarter ended on 30th June 2025 being submitted by the Parent Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended).
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with the Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

BRANCH OFFICES :

C-2, UGF, FRONT SIDE, RAJAPURI ROAD, NEAR SHANTI NURSING HOME, UTTAM NAGAR, NEW DELHI - 110059

10-E, MALVIYA COMPLEX, LANE NEXT TO NO EXIT, MOHAN MALVIYA ROAD, AMRITSAR - 143001

Email : vijaymehrac@gmail.com, caamithanda@gmail.com, caashishraja09@gmail.com, caradhikagoel@gmail.com





CA Amit Handa
F.C.A DISA (ICAI), LL.B, LL.M
(Partner)
9878887600

VIJAY MEHRA & CO.

CHARTERED ACCOUNTANTS

Head Office : D-351, Ranjit Avenue, Amritsar.

CA Ashish Raja
F.C.A. Dip. IFRS B.Com
(Partner)
9899032170

CA Radhika Goel
F.C.A , B.com (Hons.)
(Partner)
9915460831

Ref: _____

Date : 11/8/25

4. The Statement includes the results of the following entities:

Kwality Pharmaceuticals Africa Limitada (Foreign subsidiary)

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement of consolidated unaudited financial results prepared in accordance with applicable Indian Accounting Standards ("IndAs") and other accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. The consolidated unaudited financial results includes the interim financial statements/ financial information/ financial results of subsidiary which have not been reviewed/audited by us, whose interim financial statements/ financial information/ financial results reflect total revenue of Rs. **0.00 Lacs** for the quarter ended 30th June, 2025, total Profit /(loss) after tax of Rs. **-1.24 Lacs** and total other comprehensive income / loss of Rs. **-1.50 Lacs** for the quarter ended 30th June, 2025 as considered in the consolidated unaudited financial results. According to the information and explanations given to us by the Management, these interim financial statements / financial information / financial results are not material to the Group. Our conclusion on the Statement is not modified in respect of the above matter.

For VIJAY MEHRA & CO.
Chartered Accountants

CA AMIT HANDA
Partner

M. No: 502400

FRN: 001051N

UDIN:- 25502400BMLEIA2560



Place: Amritsar
Date: 11-08-2025

BRANCH OFFICES :

C-2, UGF, FRONT SIDE, RAJAPURI ROAD, NEAR SHANTI NURSING HOME, UTTAM NAGAR, NEW DELHI - 110059
10-E, MALVIYA COMPLEX, LANE NEXT TO NO EXIT, MOHAN MALVIYA ROAD, AMRITSAR - 143001

Email : vijaymehrac@ gmail.com, caamithanda@ gmail.com, caashishraja09@ gmail.com, caradhikagoel@ gmail.com

KWALITY PHARMACEUTICALS LIMITED
Regd. Office:- VILLAGE NAGKALAN, MAJITHA ROAD, AMRITSAR – 143601
CIN No. :- L24232PB1983PLC005426; Phone no. :- 8558820862
Email Id:- ramesh@kwalitypharma.com; Website :- www.kwalitypharma.com

Unaudited Standalone Financial Results for the Quarter Ended 30th June 2025

(Rs. in Lakhs) except EPS

Sr. No.	Particulars	Quarter Ended 30.06.2025 (Unaudited)	Quarter ended 31.03.2025 (Audited)	Quarter Ended 30.06.2024 (Unaudited)	Year Ended 31.03.2025 (Audited)
I.	Revenue from operations (Net)	11147.90	11567.64	8007.89	37019.70
II.	Other income	37.57	76.53	27.77	192.01
III.	Total Revenue (I+II)	11185.47	11644.18	8035.66	37211.71
IV.	Expenses				
	(a) Cost of materials consumed	4998.04	5228.76	3743.05	16541.24
	(b) Purchases of stock-in-trade	797.89	649.61	276.62	1590.16
		7.43	200.65	-117.98	117.24
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade				
	(d) Employee benefits expense	1215.27	1267.66	971.79	4375.98
	(e) Finance Cost	276.00	249.24	247.77	987.79
	(f) Depreciation and amortisation expense	475.98	507.89	401.86	1825.84
	(g) Other expenses	1710.82	1631.01	1398.69	6350.74
	Total expenses (IV)	9481.44	9734.82	6921.80	31789.01
V.	Profit/(Loss) from operations before Exceptional items and Tax (III-IV)	1704.03	1909.35	1113.86	5422.70
VI.	Exceptional items	.00	.00	.00	.00
VII.	Profit / (Loss) before Tax (V-VI)	1704.03	1909.35	1113.86	5422.70
VIII.	Tax expense:				
	(1) Current tax	435.89	572.83	280.34	1469.47
	(2) Deferred tax	74.92	+158.68	-3.16	-158.94
	(3) Income tax relating to earlier years	.00	45.32	.00	123.19
IX.	Profit/(Loss) after Tax (VII-VIII)	1193.22	1449.88	836.68	3988.97
X.	Other Comprehensive Income				
	(i) Items that will not be reclassified to profit or loss	15.37	3.71	9.63	-.97
	(ii) Items that will be reclassified to profit or loss	.00	.00	.00	.00
	Total Other Comprehensive Income (net of tax)	15.37	3.71	9.63	-.97
XI.	Total Comprehensive Income for the period (IX+X)	1208.59	1453.59	846.30	3988.01
XII.	Paid up Equity Share Capital (Face value Rs.10 each)	1037.62	1037.62	1037.62	1037.62
XIII.	Other Equity(excluding revaluation reserve)				25466.82
XIV.	Earnings per equity share (Non annualised) (In Rs.)				
	(1) Basic	11.50	13.97	8.06	38.44
	(2) Diluted	11.50	13.97	8.06	38.44

Date:- 11-08-2025
Place:- Amritsar

FOR KWALITY PHARMACEUTICALS LIMITED

ADITYA ARORA
Whole Time Director &
DIN: 07320410



KWALITY PHARMACEUTICALS LIMITED**Regd.Office:- VILLAGE NAGKALAN, MAJITHA ROAD, AMRITSAR, PUNJAB – 143601****CIN No. :- L24232PB1983PLC005426; Phone no. :- 8558820862****Email Id:- ramesh@kwalitypharma.com; Website :- www.kwalitypharma.com****Unaudited Consolidated Financial Results for the Quarter Ended 30th June 2025****(Rs. in Lakhs) except EPS**

Sr. No.	Particulars	Quarter Ended 30.06.2025 (Unaudited)	Quarter Ended 31.03.2025 (Audited)	Quarter Ended 30.06.2024 (Unaudited)	Year Ended 31.03.2025 (Audited)
I.	Revenue from operations (Net)	11147.90	11567.64	8007.89	37019.70
II.	Other income	37.57	76.53	27.77	192.01
III.	Total Revenue (I+II)	11185.47	11644.18	8035.66	37211.71
IV.	Expenses				
	(a) Cost of materials consumed	4998.04	5228.76	3743.05	16541.24
	(b) Purchases of stock-in-trade	797.89	649.61	276.62	1590.16
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	7.43	200.65	- 117.98	117.24
	(d) Employee benefits expense	1215.48	1268.29	972.53	4378.39
	(e) Finance Cost	276.00	249.24	247.77	987.79
	(f) Depreciation and amortisation expense	476.46	508.59	402.50	1828.96
	(g) Other expenses	1711.38	1631.58	1399.35	6353.93
	Total expenses (IV)	9482.69	9736.72	6923.84	31797.71
V.	Profit before share of profit of equity accounted investees, exceptional items and tax (III-IV)	1702.78	1907.46	1111.82	5413.99
VI.	Share of profit/(loss) of associates and joint ventures accounted for using equity method (net of income tax)	0.00	0.00	0.00	0.00
VII.	Profit before exceptional items and tax (V+VI)	1702.78	1907.46	1111.82	5413.99
VIII.	Exceptional items	.00	.00	.00	.00
IX.	Profit / (Loss) before Tax (VII-VIII)	1702.78	1907.46	1111.82	5413.99
X.	Tax expense:				
	(1) Current tax	435.89	572.83	280.34	1469.47
	(2) Deferred tax	74.92	- 158.68	- 3.16	- 158.94
	(3) Income tax relating to earlier years	.00	45.32	.00	123.19
	(4) MAT Credit (Entitlement)/Utilised	.00	0.00	0.00	0.00

XI.	Profit/(Loss) after Tax (IX-X)	1191.97	1447.99	834.64	3980.27
XII.	Other Comprehensive Income (i) Items that will not be reclassified subsequently to profit or loss Remeasurement of defined benefit plans(net Tax) (ii) Items that will be reclassified to profit or Exchange differences in translating financial statements of foreign operations	15.37 - .26	3.71 - .10	9.63 - .27	- .97 - .81
	Total Other Comprehensive Income (net of tax)	15.11	3.61	9.36	- 1.78
	Total Comprehensive Income for the period (XI+XII)	1207.08	1451.60	844.00	3978.49
XIII.	Profit/(loss) attributable to: a) Owners of the Company b) Non-controlling interests	1192.58 - .61	1448.89 - .90	835.64 - 1.00	3984.51 - 4.24
XIV.	Other comprehensive income attributable to: a) Owners of the Company b) Non-controlling interests	15.11	3.61	9.36	- 1.78
XV.	Total comprehensive income attributable to: a) Owners of the Company b) Non-controlling interests	1207.69 - .61	1452.50 - .90	845.00 - 1.00	3982.73 - 4.24
XVI.	Paid up Equity Share Capital (Face value Rs.10 each)	1037.62	1037.62	1037.62	1037.62
XVII.	Other Equity(excluding revaluation reserve)				25287.21
XVIII.	Earnings per equity share (Non annualised) (In Rs.)				
	(1) Basic	11.49	13.95	8.04	38.36
	(2) Diluted	11.49	13.95	8.04	38.36

***Basic and Diluted EPS for all periods except for year ended 31st March 2025 is not annualised**

FOR KWALITY PHARMACEUTICALS LIMITED

Date:- 11-08-2025

Place:- Amritsar

ADITYA AROH
Whole Time Director
DIN: 07320410





KWALITY PHARMACEUTICALS LIMITED

Regd. Office:- VILLAGE NAGKALAN, MAJITHA ROAD, AMRITSAR – 143601

CIN No.:- L24232PB1983PLC005426; Phone no. :- 8558820863

Email Id:-ramesh@kwalitypharma.com; Website :- www.kwalitypharma.com

Notes:

1. The Financial Results of the Company for the Quarter Ended June 30, 2025 have been reviewed by the Audit Committee on 11th August, 2025 and approved by the Board of Directors of the Company in their meeting held on 11th August, 2025. The statutory auditors have carried out limited review of the results for the quarter ended 30th June, 2025 and have issued an unmodified review report.
2. The Financial Results have been prepared in accordance with the requirements of Indian Accounting Standards 34 "Interim Financial Reporting" ("Ind-AS 34") notified under section 133 of the Companies Act, 2013 and Regulation 33 of Securities and Exchange Board of India (Listing obligations and Disclosure Requirements) Regulations, 2015, as amended.
3. The Company is primarily engaged in the business of Pharmaceuticals which is single reportable segment for the quarter ended 30th June, 2025 as per Accounting Standard 17 on segment reporting notified under the Companies (Accounting Standards) Rules 2014 and hence no separate segment reporting is given.
4. Previous period figures have been regrouped/rearranged, wherever necessary, to correspond to current period's presentation.
5. The above Financial Results are also available on our website www.kwalitypharma.com and Stock Exchange website www.bseindia.com.
6. The figures for the quarter ended 31st March 2025 are the balancing figures between the audited figures in respect of the full financial year ended 31st March 2025 and the unaudited published year-to-date figures upto 31st December 2024, being the date of end of the third quarter of the financial year ended 31st March 2025 which were reviewed by the statutory auditors.
7. The Earning per Share (EPS) has been calculated as per Accounting Standard on Earning Per Share (AS 20).

FOR AND ON BEHALF OF THE BOARD
For KWALITY PHARMACEUTICALS LIMITED


Aditya Arora
Whole Time Director & CFO
DIN: 07320410



Date: 11-08-2025
Place: Amritsar